These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
301 related articles for article (PubMed ID: 32394761)
21. Comparison of breast-conserving surgery with mastectomy in locally advanced breast cancer after good response to neoadjuvant chemotherapy: A PRISMA-compliant systematic review and meta-analysis. Sun Y; Liao M; He L; Zhu C Medicine (Baltimore); 2017 Oct; 96(43):e8367. PubMed ID: 29069026 [TBL] [Abstract][Full Text] [Related]
22. The use of a second core needle biopsy to predict response to neoadjuvant chemotherapy in breast cancer patients, especially in the HER2-positive population. Zhang Y; Shen J; Wu S; Zhou Y; Shao Z; Liu G Surgery; 2020 Dec; 168(6):1115-1121. PubMed ID: 32917430 [TBL] [Abstract][Full Text] [Related]
23. Comparison of hazard models with and without consideration of competing risks to assess the effect of neoadjuvant chemotherapy on locoregional recurrence among breast cancer patients. Pathak M; S Deo SNV; Dwivedi SN; Vishnubhatla S; Thakur B J Cancer Res Ther; 2021; 17(4):982-987. PubMed ID: 34528552 [TBL] [Abstract][Full Text] [Related]
24. Pathological complete response in invasive breast cancer treated by skin sparing mastectomy and immediate reconstruction following neoadjuvant chemotherapy and radiation therapy: Comparison between immunohistochemical subtypes. Barrou J; Bannier M; Cohen M; Lambaudie E; Gonçalves A; Bertrand P; Buttarelli M; Opinel P; Sterkers N; Tallet A; Zinzindohoué C; Houvenaeghel G Breast; 2017 Apr; 32():37-43. PubMed ID: 28033508 [TBL] [Abstract][Full Text] [Related]
25. [Phase II clinical trial of neoadjuvant therapy with carboplatin plus paclitaxel for locally advanced triple-negative breast cancer]. Ma WY; Zhang P; Zhang BL; Wang X; Xu XZ; Zheng S; Wang JY; Cai RG; Yuan P; Ma F; Fan Y; Xu BH Zhonghua Zhong Liu Za Zhi; 2012 Oct; 34(10):770-4. PubMed ID: 23291072 [TBL] [Abstract][Full Text] [Related]
26. Identifying accessible prognostic factors for breast cancer relapse: a case-study on 405 histologically confirmed node-negative patients. Zemni I; Ghalleb M; Jbir I; Slimane M; Ben Hassouna J; Ben Dhieb T; Bouzaiene H; Rahal K World J Surg Oncol; 2017 Nov; 15(1):206. PubMed ID: 29169398 [TBL] [Abstract][Full Text] [Related]
27. The dynamic change of neutrophil to lymphocyte ratio is predictive of pathological complete response after neoadjuvant chemotherapy in breast cancer patients. Dan J; Tan J; Huang J; Zhang X; Guo Y; Huang Y; Yang J Breast Cancer; 2020 Sep; 27(5):982-988. PubMed ID: 32306184 [TBL] [Abstract][Full Text] [Related]
28. Better predictive value of axillary lymph node (ALN) status after systemic therapy for operable HER2-overexpressing breast cancer: A single-institution retrospective study. Zhang Y; Mo M; Li JW; Zhou Y; Wu J; Yu KD; Shen ZZ; Shao ZM; Liu GY Eur J Surg Oncol; 2016 Aug; 42(8):1146-52. PubMed ID: 27365197 [TBL] [Abstract][Full Text] [Related]
29. Tumor Biology and Response to Chemotherapy Impact Breast Cancer-specific Survival in Node-positive Breast Cancer Patients Treated With Neoadjuvant Chemotherapy: Long-term Follow-up From ACOSOG Z1071 (Alliance). Boughey JC; Ballman KV; McCall LM; Mittendorf EA; Symmans WF; Julian TB; Byrd D; Hunt KK Ann Surg; 2017 Oct; 266(4):667-676. PubMed ID: 28657941 [TBL] [Abstract][Full Text] [Related]
30. Predicting nodal status using dynamic contrast-enhanced magnetic resonance imaging in patients with locally advanced breast cancer undergoing neoadjuvant chemotherapy with and without sequential trastuzumab. Hsiang DJ; Yamamoto M; Mehta RS; Su MY; Baick CH; Lane KT; Butler JA Arch Surg; 2007 Sep; 142(9):855-61; discussion 860-1. PubMed ID: 17875840 [TBL] [Abstract][Full Text] [Related]
31. Lymph node counts and ratio in axillary dissections following neoadjuvant chemotherapy for breast cancer: a better alternative to traditional pN staging. Chen S; Liu Y; Huang L; Chen CM; Wu J; Shao ZM Ann Surg Oncol; 2014 Jan; 21(1):42-50. PubMed ID: 24013900 [TBL] [Abstract][Full Text] [Related]
32. Oncologic Safety of Immediate Breast Reconstruction in Breast Cancer Patients Who Underwent Neoadjuvant Chemotherapy: Short-Term Outcomes of a Matched Case-Control Study. Ryu JM; Park S; Paik HJ; Nam SJ; Kim SW; Lee SK; Yu J; Bae SY; Kim I; Bang SI; Mun GH; Pyon JK; Jeon BJ; Lee JE Clin Breast Cancer; 2017 Jun; 17(3):204-210. PubMed ID: 28065399 [TBL] [Abstract][Full Text] [Related]
33. Impact of age on pathological complete response and locoregional recurrence in locally advanced breast cancer after neoadjuvant chemotherapy. Chou HH; Kuo WL; Yu CC; Tsai HP; Shen SC; Chu CH; Yu MC; Lo YF; Dabora MA; Chang HK; Lin YC; Ueng SH; Chen SC Biomed J; 2019 Feb; 42(1):66-74. PubMed ID: 30987708 [TBL] [Abstract][Full Text] [Related]
34. The predictive potential of Neuronatin for neoadjuvant chemotherapy of breast cancer. Pieper W; Ignatov A; Kalinski T; Haybaeck J; Czapiewski P; Nass N Cancer Biomark; 2021; 32(2):161-173. PubMed ID: 34092612 [TBL] [Abstract][Full Text] [Related]
35. The accuracy of MRI in detecting pathological complete response following neoadjuvant chemotherapy in different breast cancer subtypes. Kuzmova M; Cullinane C; Rutherford C; McCartan D; Rothwell J; Evoy D; Geraghty J; Prichard RS Surg Oncol; 2023 Dec; 51():102011. PubMed ID: 37931546 [TBL] [Abstract][Full Text] [Related]
36. A Randomized Parallel Controlled Phase II Trial of Recombinant Human Endostatin Added to Neoadjuvant Chemotherapy for Stage III Breast Cancer. Zhang X; Zhang Z; Cao M; Liu B; Mori M; Luoh SW; Bergan R; Liu Y; Liu Y Clin Breast Cancer; 2020 Aug; 20(4):291-299.e3. PubMed ID: 32482525 [TBL] [Abstract][Full Text] [Related]
37. Effect of Neoadjuvant Chemotherapy on Axillary Lymph Node Positivity and Numbers in Breast Cancer Cases. Uyan M; Koca B; Yuruker S; Ozen N Asian Pac J Cancer Prev; 2016; 17(3):1181-5. PubMed ID: 27039745 [TBL] [Abstract][Full Text] [Related]
38. Investigating the Association Between Type 2 Diabetes Mellitus and Pathological Responses Among Breast Cancer Patients Receiving Neoadjuvant Chemotherapy. Javed S; Mohamed Noor DA; Md Hanafiah NH; Javed U; Mustafa T; Rehman AU; Harun SN J Surg Res; 2024 Jul; 299():85-93. PubMed ID: 38718688 [TBL] [Abstract][Full Text] [Related]
39. Summated chemotherapy dose-intensity versus loco-regional response in locally advanced breast cancer: its possible implications. Datta NR; Rajkumar A; Basu R Indian J Cancer; 2003; 40(4):127-34. PubMed ID: 14716108 [TBL] [Abstract][Full Text] [Related]
40. Neoadjuvant systemic therapy for breast cancer: the Westmead experience. Cocco AM; Messer D; Brown A; Sriram N; Gilchrist J; Al-Mansouri L; Kefford R; Meybodi F; French J; Hsu J; Elder E ANZ J Surg; 2018 Jun; 88(6):640-644. PubMed ID: 28922685 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]